全文获取类型
收费全文 | 5579篇 |
免费 | 284篇 |
国内免费 | 34篇 |
专业分类
耳鼻咽喉 | 71篇 |
儿科学 | 138篇 |
妇产科学 | 162篇 |
基础医学 | 704篇 |
口腔科学 | 146篇 |
临床医学 | 375篇 |
内科学 | 1449篇 |
皮肤病学 | 110篇 |
神经病学 | 516篇 |
特种医学 | 142篇 |
外科学 | 920篇 |
综合类 | 31篇 |
预防医学 | 324篇 |
眼科学 | 82篇 |
药学 | 236篇 |
中国医学 | 15篇 |
肿瘤学 | 476篇 |
出版年
2023年 | 53篇 |
2022年 | 114篇 |
2021年 | 285篇 |
2020年 | 120篇 |
2019年 | 217篇 |
2018年 | 229篇 |
2017年 | 165篇 |
2016年 | 138篇 |
2015年 | 143篇 |
2014年 | 226篇 |
2013年 | 291篇 |
2012年 | 460篇 |
2011年 | 521篇 |
2010年 | 262篇 |
2009年 | 239篇 |
2008年 | 357篇 |
2007年 | 364篇 |
2006年 | 345篇 |
2005年 | 327篇 |
2004年 | 256篇 |
2003年 | 240篇 |
2002年 | 208篇 |
2001年 | 28篇 |
2000年 | 28篇 |
1999年 | 44篇 |
1998年 | 43篇 |
1997年 | 28篇 |
1996年 | 15篇 |
1995年 | 20篇 |
1994年 | 14篇 |
1993年 | 18篇 |
1992年 | 13篇 |
1991年 | 11篇 |
1990年 | 7篇 |
1989年 | 7篇 |
1988年 | 4篇 |
1987年 | 4篇 |
1986年 | 4篇 |
1984年 | 6篇 |
1983年 | 4篇 |
1982年 | 2篇 |
1981年 | 9篇 |
1980年 | 3篇 |
1979年 | 2篇 |
1978年 | 2篇 |
1977年 | 2篇 |
1976年 | 2篇 |
1974年 | 2篇 |
1973年 | 2篇 |
1920年 | 1篇 |
排序方式: 共有5897条查询结果,搜索用时 15 毫秒
91.
Jose R. Gonzalez‐Porras Fernando Escalante Emilia Pardal Magdalena Sierra Luis J. Garcia‐Frade Santiago Redondo Maryam Arefi Carlos Aguilar Fernando Ortega Erik de Cabo Rosa M. Fisac Oscar Sanz Carmen Esteban Ignacio Alberca Mercedes Sanchez‐Barba Maria T. Santos Abel Fernandez Tomas J. Gonzalez‐Lopez representing the Grupo de Trombosis y Hemostasia de Castilla y León 《European journal of haematology》2013,91(3):236-241
92.
Hernando V Sobrino-Vegas P Burriel MC Berenguer J Navarro G Santos I Reparaz J Martínez MA Antela A Gutiérrez F Del Amo J;for CoRIS cohort 《AIDS (London, England)》2012,26(14):1829-1834
OBJECTIVES:: To compare causes of death (CoDs) from two independent sources: National Basic Death File (NBDF) and deaths reported to the Spanish HIV Research cohort [Cohort de adultos con infección por VIH de la Red de Investigación en SIDA CoRIS)] and compare the two coding algorithms: International Classification of Diseases, 10th revision (ICD-10) and revised version of Coding Causes of Death in HIV (revised CoDe). METHODS:: Between 2004 and 2008, CoDs were obtained from the cohort records (free text, multiple causes) and also from NBDF (ICD-10). CoDs from CoRIS were coded according to ICD-10 and revised CoDe by a panel. Deaths were compared by 13 disease groups: HIV/AIDS, liver diseases, malignancies, infections, cardiovascular, blood disorders, pulmonary, central nervous system, drug use, external, suicide, other causes and ill defined. RESULTS:: There were 160 deaths. Concordance for the 13 groups was observed in 111 (69%) cases for the two sources and in 115 (72%) cases for the two coding algorithms. According to revised CoDe, the commonest CoDs were HIV/AIDS (53%), non-AIDS malignancies (11%) and liver related (9%), these percentages were similar, 57, 10 and 8%, respectively, for NBDF (coded as ICD-10). When using ICD-10 to code deaths in CoRIS, wherein HIV infection was known in everyone, the proportion of non-AIDS malignancies was 13%, liver-related accounted for 3%, while HIV/AIDS reached 70% due to liver-related, infections and ill-defined causes being coded as HIV/AIDS. CONCLUSION:: There is substantial variation in CoDs in HIV-infected persons according to sources and algorithms. ICD-10 in patients known to be HIV-positive overestimates HIV/AIDS-related deaths at the expense of underestimating liver-related diseases, infections and ill defined causes. CoDe seems as the best option for cohort studies. 相似文献
93.
Viviana Marin-Torres Justo Valverde Aliaga Ignacio Sánchez Miró María Isabel Sáenz del Castillo Vicente Elena Polentinos-Castro Araceli Garrido Barral 《Atencion primaria / Sociedad Espa?ola de Medicina de Familia y Comunitaria》2013,45(1):46-53
ObjectiveTo describe the use of the Internet by primary care patients to seek health related information, understand how they are influenced by this information, and evaluate its impact on the doctor-patient relationship.DesignCross sectional study, through self-administered survey.SettingOne urban health center in Madrid.ParticipantsA total of 323 questionnaires were collected from patients between 14 and 75 years old who attended a physician's office for any reason, excluding illiterate patients and those with neurological or psychiatric problems preventing them from completing the survey.MeasurementsInternet usage, ability of the internet to clarify doubts regarding health issues, patient lifestyle changes, socio-demographic variables, and physician's receptivity to the use of internet by patients.Results61% (CI 95%: 56%-67%) of patients used the Internet as a source of health information: Internet queries were able to address health doubts in 92.4% of users, 53.5% reported that the Internet changed their thinking about their health in at least one instance, 30% made behavioral changes (of which 60.1% discussed these changes with their physician), 44.3% had more questions at the physician's office, and 80.8% believe that the doctor would be willing to talk about the information found on the internet.ConclusionsUsing the Internet to find information about health is very common, with positive influence on physician-patient relationship. This may be useful for achieving behavioral changes in patients and can be used as a tool in medical practice. 相似文献
94.
95.
Lorena Álvarez-Rodríguez Marcos López-Hoyos Eugenio Carrasco-Marín Cristina Mata Jaime Calvo-Alén Elena Aurrecoechea Ricardo Blanco Teresa Ruiz Pedro Muñoz Cacho Ignacio Villa Víctor Manuel Martínez-Taboada 《Reumatología clinica》2012,8(6):321-327
ObjectiveTo investigate whether there is association between the rs20541 (R130Q) polymorphism in the IL-13 gene with disease susceptibility and clinical subsets in patients with elderly-associated inflammatory chronic diseases.Material and methods78 patients with giant cell arteritis (GCA), 174 with polymyalgia rheumatica (PMR), 90 elderly-onset rheumatoid arthritis (EORA), and 465 healthy controls from the same geographic area were studied. The rs20541 (R130Q) polymorphism in the IL-13 gene was evaluated by PCR-RFLP. Circulating levels of IL-13 were measured by ELISA.ResultsA higher frequency of the AA genotype [2.349 (0.994-5.554)], as well as the allele A [1.589 (1.085-2.328] and the A carriers [1.656 (1.021-2.686)] (p < 0.05) was observed in the GCA patients. No significant differences were observed in the PMR and EORA patients as compared with the healthy controls. Neither difference was observed among the different disease groups studied. In GCA patients, differences in the genotype were associated with a worse prognosis. In PMR patients, the AA genotype was associated with higher levels of serum IL-13 than the GA one. However, such an association was not detected for controls and the other disease groups.ConclusionsGCA is more frequent in carriers of the rs20541 (R130Q) polymorphism in the IL-13 gene. The utility of this polymorphism to predict the GCA prognosis must be confirmed in studies with a higher number of patients. 相似文献
96.
Fabián Matías Caro María Laura Alberti Federico Campins Juan Ignacio Enghelmayer Martín Eduardo Fernández Diana Lancellotti Tulio Papucci Javier Adrián Sebastiani Francisco Paulin 《Archivos de bronconeumologia》2019,55(2):75-80
Introduction
Pirfenidone was the first antifibrotic drug approved in Argentina for idiopathic pulmonary fibrosis (IPF). Outcomes in real life may differ from the results of clinical trials. The primary endpoint was to study the tolerance of pirfenidone in real life. Secondary endpoints were to analyze effectiveness and reasons for discontinuation.Materials and methods
Retrospective observational study conducted in four specialized centers in Argentina. We analyzed the medical records of patients with IPF who received pirfenidone between June 2013 and September 2016. Adverse events (AE) and the variables that could influence these results were analyzed. Forced vital capacity (FVC%) parameters were also compared between the pre-pirfenidone and post-pirfenidone periods.Results
Fifty patients were included, 38 (76%) men, with mean age (SD) 67.8 (8.36) years. Mean (SD) exposure to pirfenidone was 645.68 (428.19) days, with a mean daily dose (SD) of 2064.56 mg (301.49). Nineteen AEs in 15 patients (30%) were reported: nausea (14%), asthenia (10%) and skin rash (8%). A total of 18 patients (36%) interrupted treatment, only 1 definitively. The most frequent reason for discontinuation was failure of suppliers to provide the drug (9 subjects; 18%). We compared the evolution of FVC% between the pre-pirfenidone and post-pirfenidone periods, and found a mean (SD) FVC% decline of 4.03% (7.63) pre-pirfenidone and 2.64% (7.1) post-pirfenidone (P=.534).Conclusions
In our study, pirfenidone was well tolerated and associated with a reduction in FVC decline, although without reaching statistical significance. 相似文献97.
Escarlata Angullo-Martínez Enrique Carretero-Anibarro Ignacio Manuel Snchez Barrancos Xavier Cos Claramunt Domingo Orozco Beltrn Jos Luis Torres Baile Patxi Ezkurra Loiola en representacin del Grupo de Trabajo de Diabetes de la SemFyC en representacin del Grupo de Trabajo de Diabetes de la SemFyC 《Atencion primaria / Sociedad Espa?ola de Medicina de Familia y Comunitaria》2021,53(4)
Las circunstancias actuales provocadas por la COVID-19 nos obligan a los profesionales de atención primaria a idear nuevas formas de garantizar la atención sanitaria de nuestros pacientes con diabetes tipo 2 (DM2). Existen evidencias que respaldan la eficacia de la telemedicina en el control glucémico de los pacientes con DM2. Ante la rápida adaptación de la práctica clínica al uso de la telemedicina, el Grupo de Trabajo de Diabetes de la Sociedad Española de Medicina Familiar y Comunitaria (SemFyC) optó por elaborar un documento de consenso plasmado en un algoritmo de actuación/seguimiento telemático en la atención de los pacientes con DM2.Palabras clave: Telemedicina, Diabetes mellitus tipo 2, COVID-19 相似文献
98.
99.
100.
AndrewJ. Stott Michel C. Maillard Vahri Beaumont David Allcock Omar Aziz Alexander H. Borchers Wesley Blackaby Perla Breccia Gillian Creighton-Gutteridge Alan F. Haughan Rebecca E. Jarvis Christopher A. Luckhurst Kim L. Matthews George McAllister Scott Pollack Elizabeth Saville-Stones Amanda J. Van de Poël Huw D. Vater Julie Vann Rachel Williams Dawn Yates Ignacio Muoz-Sanjun Celia Dominguez 《ACS medicinal chemistry letters》2021,12(3):380
Using an iterative structure–activity relationship driven approach, we identified a CNS-penetrant 5-(trifluoromethyl)-1,2,4-oxadiazole (TFMO, 12) with a pharmacokinetic profile suitable for probing class IIa histone deacetylase (HDAC) inhibition in vivo. Given the lack of understanding of endogenous class IIa HDAC substrates, we developed a surrogate readout to measure compound effects in vivo, by exploiting the >100-fold selectivity compound 12 exhibits over class I/IIb HDACs. We achieved adequate brain exposure with compound 12 in mice to estimate a class I/IIb deacetylation EC50, using class I substrate H4K12 acetylation and global acetylation levels as a pharmacodynamic readout. We observed excellent correlation between the compound 12 in vivo pharmacodynamic response and in vitro class I/IIb cellular activity. Applying the same relationship to class IIa HDAC inhibition, we estimated the compound 12 dose required to inhibit class IIa HDAC activity, for use in preclinical models of Huntington’s disease. 相似文献